Literature DB >> 16168933

Symptomatic therapy and neurorehabilitation in multiple sclerosis.

Jürg Kesselring1, Serafin Beer.   

Abstract

Multiple sclerosis (MS) is associated with a variety of symptoms and functional deficits that result in a range of progressive impairments and handicap. Symptoms that contribute to loss of independence and restrictions in social activities lead to continuing decline in quality of life. Our aim is to give an updated overview on the management of symptoms and rehabilitation measures in MS. Appropriate use of these treatment options might help to reduce long-term consequences of MS in daily life. First, we review treatment of the main symptoms of MS: fatigue, bladder and bowel disturbances, sexual dysfunction, cognitive and affective disorders, and spasticity. Even though these symptomatic therapies have benefits, their use is limited by possible side-effects. Moreover, many common disabling symptoms, such as weakness, are not amenable to drug treatment. However, neurorehabilitation has been shown to ease the burden of these symptoms by improving self-performance and independence. Second, we discuss comprehensive multidisciplinary rehabilitation and specific treatment options. Even though rehabilitation has no direct influence on disease progression, studies to date have shown that this type of intervention improves personal activities and ability to participate in social activities, thereby improving quality of life. Treatment should be adapted depending on: the individual patient's needs, demands of their surrounding environment, type and degree of disability, and treatment goals. Improvement commonly persists for several months beyond the treatment period, mostly as a result of reconditioning and adaptation and appropriate use of medical and social support at home. These findings suggest that quality of life is determined by disability and handicap more than by functional deficits and disease progression.

Entities:  

Mesh:

Year:  2005        PMID: 16168933     DOI: 10.1016/S1474-4422(05)70193-9

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN: 1474-4422            Impact factor:   44.182


  52 in total

1.  Assessment of gait parameters and fatigue in MS patients during inpatient rehabilitation: a pilot trial.

Authors:  Rosaria Sacco; Rita Bussman; Peter Oesch; Jürg Kesselring; Serafin Beer
Journal:  J Neurol       Date:  2010-11-15       Impact factor: 4.849

Review 2.  Rehabilitation interventions in multiple sclerosis: an overview.

Authors:  Serafin Beer; Fary Khan; Jürg Kesselring
Journal:  J Neurol       Date:  2012-07-08       Impact factor: 4.849

3.  Frequency of current utilisation of complementary and alternative medicine by patients with multiple sclerosis.

Authors:  Annett Apel; Brigitte Greim; Nicolaus König; Uwe K Zettl
Journal:  J Neurol       Date:  2006-06-19       Impact factor: 4.849

Review 4.  Community neurorehabilitation: a synthesis of current evidence and future research directions.

Authors:  Sarah E Chard
Journal:  NeuroRx       Date:  2006-10

5.  Multiple sclerosis fatigue relief by bilateral somatosensory cortex neuromodulation.

Authors:  Franca Tecchio; Andrea Cancelli; Carlo Cottone; Giancarlo Zito; Patrizio Pasqualetti; Anna Ghazaryan; Paolo Maria Rossini; Maria Maddalena Filippi
Journal:  J Neurol       Date:  2014-05-23       Impact factor: 4.849

Review 6.  Specialized Pro-Resolving Lipid Mediators: Emerging Therapeutic Candidates for Multiple Sclerosis.

Authors:  Insha Zahoor; Shailendra Giri
Journal:  Clin Rev Allergy Immunol       Date:  2021-04       Impact factor: 8.667

Review 7.  [Coping with multiple sclerosis in partnerships: a systematic review of the literature].

Authors:  A-K Busch; R Spirig; W Schnepp
Journal:  Nervenarzt       Date:  2014-06       Impact factor: 1.214

Review 8.  [Multiple sclerosis : rehabilitation and long-term course].

Authors:  S Beer; J Kesselring
Journal:  Ophthalmologe       Date:  2014-08       Impact factor: 1.059

9.  Utilization of physical rehabilitation among people with multiple sclerosis.

Authors:  I Milivojević; I Adamec; M Habek
Journal:  Ir J Med Sci       Date:  2013-01-22       Impact factor: 1.568

10.  Characterization of functioning in multiple sclerosis using the ICF.

Authors:  Lisa Holper; Michaela Coenen; Andrea Weise; Gerold Stucki; Alarcos Cieza; Jürg Kesselring
Journal:  J Neurol       Date:  2010-01       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.